-transparent.png){kind=logo}
Orally active converting enzyme inhibitor (Captopril, SQ 14225) was administered in a dose of 50 mg to 12 normotensive subjects (Group I), 26 essential hypertensive patients (Group II) and 8 renovascular hypertensive patients (Group III). In Group III, 5 of 8 patients had control plasma renin activity (PRA) similar to those in Group I and II patients, but the PRA response to the administration of Captopril was greater in 7 of 8 patients than that in Groups I and II. These 7 patients had either bilateral or unilateral main renal artery stenosis. Captopril caused no increase in PRA in the remaining 1 who had unilateral renal artery stenosis with contralateral renal aplasia. It is concluded that this provocation test is useful as a screening procedure for the diagnosis of renovascular hypertension.
Y Imai, and
K Abe, and
Y Otsuka, and
Y Sakurai, and
K Yoshinaga
September 1981,
Revista clinica espanola,
Y Imai, and
K Abe, and
Y Otsuka, and
Y Sakurai, and
K Yoshinaga
October 1980,
European journal of pharmacology,
Y Imai, and
K Abe, and
Y Otsuka, and
Y Sakurai, and
K Yoshinaga
May 1982,
Israel journal of medical sciences,
Y Imai, and
K Abe, and
Y Otsuka, and
Y Sakurai, and
K Yoshinaga
November 1978,
Clinical science and molecular medicine,
Y Imai, and
K Abe, and
Y Otsuka, and
Y Sakurai, and
K Yoshinaga
June 1979,
Endocrinologia japonica,
Y Imai, and
K Abe, and
Y Otsuka, and
Y Sakurai, and
K Yoshinaga
June 1980,
Acta endocrinologica,
Y Imai, and
K Abe, and
Y Otsuka, and
Y Sakurai, and
K Yoshinaga
January 1983,
Acta medica Scandinavica. Supplementum,
Y Imai, and
K Abe, and
Y Otsuka, and
Y Sakurai, and
K Yoshinaga
March 1980,
Fukuoka igaku zasshi = Hukuoka acta medica,
Y Imai, and
K Abe, and
Y Otsuka, and
Y Sakurai, and
K Yoshinaga
January 1981,
Nephron,
Y Imai, and
K Abe, and
Y Otsuka, and
Y Sakurai, and
K Yoshinaga
April 1982,
Nihon Jinzo Gakkai shi,
